Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 30, 2022
Reporting Period: Single event date (March 30, 2022)
Business Context: The filing serves to distribute a slide deck (Exhibit 99.1) intended for use in a company presentation. The registrant is an emerging growth company incorporated in Nevada.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to attach a presentation and does not contain financial statements or quantitative performance data.
Material Changes
No material changes to financial position or operations are reported in this document. The filing is limited to the distribution of presentation materials.
Guidance, Outlook, and Risks
- Management Commentary: The Company states that the information in the attached presentation is summary in nature and should be considered in the context of other SEC filings and public announcements.
- Forward-Looking Statements: The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation, though it may do so at management's discretion.
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Presentation) for specific operational updates or strategic details not included in this summary.
- Verify the most recent financial data in the Company's latest 10-K or 10-Q filings, as this 8-K contains no financial metrics.
- Confirm the status of the Company as an emerging growth company and any associated reporting exemptions.